Observing children with achondroplasia over time

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational natural history study that will collect anthropometric measurements, clinical characteristics, comorbidities, treatments, and health-related quality of life in children with genetically confirmed achondroplasia. Participants will be followed for at least 6 months and up to 2 years with scheduled visits at pediatric specialty centers. The study enrolls ambulatory children aged ≥2.5 to <11 years who are Tanner Stage 1 and collects data to characterize growth patterns, complications, and treatment use. No investigational interventions are administered as part of this observation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Prior to screening, the guardians and children with ACH (if applicable) must be willing and able to provide signed informed consent.
2. Clinical diagnosis of ACH confirmed FGFR3 mutation by genetic testing.
3. Male or female aged ≥2.5 to \<11 years old at screening.
4. Tanner Stage 1 breast development for females or Tanner Stage 1 external genitalia development for males at screening.
5. Ambulatory and able to stand without assistance.

Exclusion Criteria:

1. Bone age ≥14 years as assessed by the investigator based on hand and wrist X-ray taken within 6 months prior to Day 1.
2. Current evidence of growth plate closure (proximal tibia, distal femur), or AGV ≤ 1.5 cm/year over a period ≥6 months prior to screening.
3. Have a form of skeletal dysplasia other than ACH or known medical conditions that result in short stature or abnormal growth, including but not limited to severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Turner syndrome, pseudoachondroplasia, inflammatory bowel disease, chronic renal insufficiency, active celiac disease a, Vitamin D deficiency b, untreated hypothyroidism c, poorly controlled diabetes (HbA1c ≥8.0%) or diabetic complications d.

   1. Celiac disease responsive to a gluten-free diet is allowed
   2. Vitamin D deficiency or insufficiency with a 25-hydroxyvitamin D \[25- (OH) D\] level ≥ 30 nmol/L after supplementation is allowed. Vitamin D deficiency is defined as 25-(OH) D level \<30 nmol/L. Vitamin D insufficiency is defined as 25-(OH) D level 30\~50 nmol/L. Patients with Vitamin D deficiency or insufficiency must be on Vitamin D regimen prior to screening
   3. Patients with hypothyroidism meeting the following criteria are allowed to enroll: must be clinically euthyroid for one month prior to screening and, in the opinion of the investigator, have achieved any catch-up growth expected from thyroxine replacement
   4. Patients with diabetes must have been on stable medication regimen for 3 months prior to screening
4. History or presence of injury or disease of the growth plate(s), other than ACH, that affects growth potential of long bones.
5. Impaired cardiac function or clinically significant cardiovascular disease, including any one of the following: New York Heart Association class II or higher heart disease, congenital heart disease (patients with repaired uncomplicated patent ductus arteriosus or atrial/ventricular septal defect with repair are allowed), clinically significant arrhythmias requiring therapy, aortic regurgitation, congestive heart failure, or any other uncontrolled heart disease.
6. For ACH-related complications: Current severe sleep apnea, symptomatic and/or requiring intervention for hydrocephalus, or spinal cord compression at the cranio-cervical junction, and has previously undergone ventriculoperitoneal shunt surgery.
7. Bone fracture within 6 months prior to screening (within 2 months for finger and toe fractures).
8. Have received any dose of medications affecting stature or body proportionality, such as human growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids within 3 months prior to screening, or long-term treatment (\>3 months) with the above drugs at any time.
9. Prior treatment with any CNP analogues or FGFR inhibitors. Prior use of any investigational drugs or investigational medical devices that affect stature or body proportionality.
10. Any comorbidities, disease or condition that, in the opinion of the investigator, may make the patient unlikely to fully complete the study-related procedures, may affect protocol compliance.

Where it's running

• Beijing Children's Hospital, Capital Medical University
  Beijing, Beijing Municipality, China Recruiting
• Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting
• Xin Hua Hospital Affiliatod to Shanghai Jiao Tong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting
• Guangzhou Women and Childrens Medical Center
  Guangzhou, Guangzhou, China Not yet recruiting
• Henan Children's Hospital, Zhengzhou Children's Hospital
  Zhengzhou, Henan, China Not yet recruiting
• Chengdu Women's and Children's Central Hospital
  Chengdu, Sichuan, China Not yet recruiting

Study contacts

• Study coordinator: Jing Zhang
• Email: jing.zhang@abbisko.com
• Phone: +86-15002126439

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BMN 333 versus daily vosoritide for growth in children with achondroplasia

  This trial tests whether weekly BMN 333 injections help children with achondroplasia grow as well as daily vosoritide.

  Recruiting at 25 sites Phase 2/3 BioMarin Pharmaceutical · Oakland, California and 27 other locations · NCT07441876

• Measuring limb movement in people with FGFR3-related skeletal dysplasia

  This project will try using Syde® wearable movement recordings to see which measurements reliably track limb movement in people aged 3 and older with achondroplasia or hypochondroplasia.

  Recruiting Sysnav · Liège and 3 other locations · NCT07388966

• Infigratinib treatment for children under 3 with achondroplasia

  This trial tests whether daily oral infigratinib helps children younger than 3 years who have achondroplasia.

  Recruiting at 12 sites Phase 2 QED Therapeutics, a BridgeBio company · Oakland, California and 11 other locations · NCT07169279

• Evaluating TYRA-300 for children with achondroplasia

  This study is testing a new medication called TYRA-300 to see if it is safe and helps children aged 3 to 10 with achondroplasia grow better.

  Recruiting at 25 sites Phase 2 Tyra Biosciences, Inc · Torrance, California and 24 other locations · NCT06842355

• Observational study of achondroplasia in the US

  This study looks at children in the U.S. with achondroplasia to see how they are doing with and without the treatment VOXZOGO™ over at least five years.

  Recruiting at 8 sites BioMarin Pharmaceutical · Oakland, California and 7 other locations · NCT06168201

• Evaluating a new treatment for infants with achondroplasia

  This study is testing a new treatment for infants with achondroplasia to see if it helps them grow better compared to a placebo.

  Recruiting at 18 sites Phase 2 Ascendis Pharma A/S · Saint Paul, Minnesota and 17 other locations · NCT06079398

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.